Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Bronchial wall thickening? 110 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 110 reports of Bronchial wall thickening have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.3% of all adverse event reports for MEPOLIZUMAB.

110
Reports of Bronchial wall thickening with MEPOLIZUMAB
0.3%
of all MEPOLIZUMAB reports
0
Deaths
32
Hospitalizations

How Dangerous Is Bronchial wall thickening From MEPOLIZUMAB?

Of the 110 reports, 32 (29.1%) required hospitalization, and 19 (17.3%) were considered life-threatening.

Is Bronchial wall thickening Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 110 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Bronchial wall thickening?

ALBUTEROL (331) PREDNISONE (280) TIOTROPIUM (250) MONTELUKAST (204) BUDESONIDE\FORMOTEROL (165) PANTOPRAZOLE (138) CICLESONIDE (128) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (125) FORMOTEROL\MOMETASONE FUROATE (125) UMECLIDINIUM (118)

Which MEPOLIZUMAB Alternatives Have Lower Bronchial wall thickening Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Bronchial wall thickening Reports All Drugs Causing Bronchial wall thickening MEPOLIZUMAB Demographics